CCX - Maine Technology Institute

CCX

We want to shorten the time between a drug’s approval and the day patients can get it, everywhere in the world.

–Nathan Sigworth, CEO and Founder, CCX

Contribuer à ce que les médicaments innovants parviennent plus rapidement aux patients

When a new medicine receives regulatory approval in Europe, patients may still have to wait months or years before they can access it.

According to the 2024 EFPIA Patients W.A.I.T. Indicator report, the average time between regulatory approval and patient access in the European Union was 578 days. Pharmaceutical companies must first negotiate pricing and reimbursement agreements with public and private insurers.

CCX is working to shorten that wait. The company established its U.S. headquarters in Portland, Maine, in 2026 to support its continued growth. CCX provides enterprise technology that helps pharmaceutical manufacturers and payers coordinate negotiations, manage agreements, and bring newly approved medicines to patients sooner.

Much of this work has traditionally been managed through spreadsheets, emails, and phone calls. CCX gives pharmaceutical teams a way to coordinate their efforts across countries and work with payers on agreements that determine when and how patients can access new treatments.

Today, CCX serves pharmaceutical companies operating in European markets, including some of the world’s five largest manufacturers and emerging biotechnology firms.

Managing the Path from Approval to Patient Access

Regulatory approval is only one part of bringing a new medicine to patients. Pharmaceutical manufacturers must also negotiate agreements that establish pricing and payment terms, often separately with public and private insurers in each country where they plan to make the medicine available.

For companies operating internationally, managing these agreements requires coordination among teams in different countries and careful tracking of existing deals.

CCX provides a platform to help manufacturers and payers manage this work. Its technology helps global and in-country teams coordinate negotiations, administer agreements, and keep track of the information needed to make decisions about bringing medicines to additional markets.

As the company expanded its work with pharmaceutical manufacturers, it saw an opportunity to help customers more easily track drug launches and pricing across countries and currencies.

CCX wanted to give clients a clearer picture of how their launches were progressing, making it easier to evaluate existing deals and pursue new ones.

Turning Launch and Price Data into Better Decisions

Pharmaceutical manufacturers must plan drug launches and negotiate prices across multiple countries, often working with different currencies. CCX wanted to help customers compare pricing agreements across markets and identify opportunities to accelerate patient access.

With funding from the Maine Technology Institute, along with strategic input from two global pharma customers, the company hired additional team members and developed a new global pricing and launch readiness dashboard.

Released in July 2026, the launch readiness dashboard gives customers several ways to examine their price and contract data.

The dashboard keeps track of all of a company’s contracts and their terms in one place. Customers can compare prices across countries, convert amounts into a common currency, and see when contracts are approaching expiration.

These tools help pharmaceutical companies monitor pricing and launch readiness across markets and make decisions about future negotiations.

For CCX, the project addressed a need the company had identified through its work with customers. Better visibility into prices and contract timelines across markets could help clients pursue more agreements and make medicines available in additional markets.

The company has received positive feedback from customers since launching the dashboard. Discussions about expanding its analytics capabilities are underway with all current clients.

Developing New Capabilities With MTI Support

CCX received Business Innovation Funding from MTI to help develop its new client dashboard. The funding allowed the company to add staff and complete development over the summer of 2026.

CCX completed and launched the production price and launch tracking dashboard on schedule and received its final funding payment in August 2026. The company also found value in MTI’s guidance as it established its U.S. headquarters in Maine.

Sigworth first connected with MTI after a friend who had built a business in the state recommended the organization.

“We’ve found the team at MTI a fantastic sounding board in addition to a financial partner,” Sigworth says.

Tom Kittredge of MTI helped CCX understand Maine’s policy environment and introduced the team to stakeholders and sources of talent in the state.

Sigworth credits Kittredge with being a valuable advisor as the company established itself in Maine. When Kittredge was on leave, Lou Simms stepped in to help. CCX has also begun working with Emily Braley, whose focus is on life sciences.

Sigworth praised MTI’s clear expectations and responsiveness throughout the funding process. Project milestones were established at the outset, and MTI reviewed CCX’s final report and approved the last payment within approximately a week.

For CCX, the relationship has provided both funding for product development and connections that have helped the company grow in Maine.

Finding Support in Maine’s Innovation Community

CCX has developed relationships with several organizations and entrepreneurs since establishing its headquarters in Portland. The company is active in Startup Maine and Maine Tech Week and has connected with the Roux Institute and other members of the state’s business community.

MTI’s life sciences team has introduced CCX to additional resources, while the company’s leaders have worked to bring together people in Maine’s life sciences and technology sectors.

CCX’s Portland-based leadership team includes CEO Nathan Sigworth, Chief Commercial Officer Scott Oehrlein, and Vice President of Customer Success Kachina Miller. The company also uses AI-assisted engineering tools to help its Maine team develop technology that supports major pharmaceutical launches around the world.

Although CCX has its U.S. headquarters in Maine, its customers currently use its technology to serve European markets, where pharmaceutical pricing and reimbursement systems create a need for the company’s services. CCX has built its business around serving those markets while growing its leadership team and operations in Portland.

Sigworth wants CCX to contribute to the same network of entrepreneurs and organizations that has supported its own growth. The company has also introduced investors and partners from outside the state to Maine’s business community.

CCX recently hosted a board meeting in Maine, bringing investors from across the United States and Europe. One participant, whose family had lived in Maine since the 1700s, remarked that it was the first business meeting he had ever attended in the state.

For Sigworth, the experience illustrated how much opportunity remains to introduce people to Maine as a place to build and grow a company.

As CCX expands internationally, the company plans to keep its leadership team anchored in Maine and continue investing in the state’s workforce and business community.

Working Toward Faster Access to Medicines

CCX’s long-term goal is to reduce the time patients must wait for newly approved medicines.

The company plans to continue developing its market access strategy, agreement administration, and analytics tools. It also expects to work with clients to make better use of their own artificial intelligence capabilities when examining agreement performance and planning access to additional markets.

CCX wants its platform to become a standard tool for pharmaceutical manufacturers and payers managing market access around the world.

The company reports that its work over the past year has supported access to innovative medicines for millions of patients who otherwise would not have had access to those treatments.

For Sigworth, the opportunity to help patients is what makes the work rewarding. He points to working with a talented team, helping people live healthier lives, and creating value for CCX’s clients and partners as the parts of the business he enjoys most.

With plans to expand its technology and add more employees in Maine, CCX will continue working with pharmaceutical manufacturers and payers to shorten the time between drug approval and patient access.

© 2026 Maine Technology Institute. Tous droits réservés. Vie privée